Neoantigen vaccine spurs immune response in glioblastoma
Glioblastoma is termed an immunologically ‘cold’ tumor – a disadvantage for treatment with immunotherapy – because the brain tumor contains very few immune cells that are required to generate an immune response against the tumor.
In a report, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells. The neoantigen vaccine approach has been pioneered in the laboratory of Catherine Wu, MD, at Dana-Farber.
“This is the first time it has been shown that a vaccine can generate immune cells against the tumor that can traffic from the bloodstream into a glioblastoma tumor,” said David Reardon, MD, senior author of the study. Reardon is clinical director of the Center for Neuro-Oncology at Dana-Farber.
Click here to read more.
9th World Congress of Neuroendoscopy
Nov. 21-24, 2019; Orlando, Fla.
Mayo Clinic Multidisciplinary Spine Care Conference 2019
Nov. 22-23, 2019; Amelia Island, Fla.
Medical and Surgical Interventions in ICH: A Practical Workshop
Nov. 23, 2019; Chicago
2nd International Conference on Brain Stimulation
Nov. 27-28, 2019; Dubai, United Arab Emirates
2019 AANS/CNS Section on Pediatric Neurological Surgery Annual Meeting
Dec. 5-8, 2019; Scottsdale, Ariz.